| 產品名稱 |
pHRV-mCD40L#3 |
| 商品貨號 |
B181884 |
| Designations |
pHRV-mCD40L#3 |
| Depositors |
Immunex Corporation, PA Perkins, MK Spriggs, Immunex Corporation |
| U.S. Patent |
|
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Biosafety Level |
1 |
| Vector Information |
Vector: pHRV-mCD40L#3 (phagemid) Promoters: Promoter for in vitro transcription PGK-1 Marker(s):ampR,neoR,HSV TK Construct size (kb): 20.29999923706055 Features: marker(s): HSV TK
marker(s): ampR
marker(s): neoR
promoter for in vitro transcription: PGK-1
replicon: pMB1
MCS: HindIII...SfiI
coding sequence: mouse CD40L |
| Applications |
contains sequences that integrate by homologous recombination CD40 antigen ligand vector for constructing knockouts CD40 antigen ligand |
| Comments |
Gene targeting vector for CD40 ligand (CD40L, CD154), useful for preparing CD40L-deficient (knockout) mice. Homologous recombination with the vector results in the removal of exons 3 and 4 from the CD40L gene. The vector can be electroporated into embryonic stem cells, for example at 200 V and 960 uF. Culture the cells on a feeder layer, and select in 175 ug/ml G418+2 mM gancyclovir, for about 10 days. Then plate single clones and analyze via PCR. |
| Media |
ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin
|
| References |
Spriggs MK, et al. Detection of mutations in a CD40 ligand gene. US Patent 5,565,321 dated Oct 15 1996
|
| Shipped |
frozen |
| Shipping Information |
Distributed: freeze-dried |
